RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines.

[1]  L. Ashman,et al.  Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. , 2003, Blood.

[2]  S. Jayasena,et al.  Functional siRNAs and miRNAs Exhibit Strand Bias , 2003, Cell.

[3]  T. Du,et al.  Asymmetry in the Assembly of the RNAi Enzyme Complex , 2003, Cell.

[4]  D. Largaespada,et al.  Gene insertion and long-term expression in lung mediated by the Sleeping Beauty transposon system. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Sabine Fritz,et al.  Transposon mutagenesis of the mouse germline. , 2003, Genetics.

[6]  I. Chen,et al.  Efficient lentiviral vectors for short hairpin RNA delivery into human cells. , 2003, Human gene therapy.

[7]  T. Buclin,et al.  Functional consequence of MDR1 expression on imatinib intracellular concentrations. , 2003, Blood.

[8]  D. Largaespada,et al.  Gene transfer into genomes of human cells by the sleeping beauty transposon system. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  H. Lage,et al.  Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi) , 2003, FEBS letters.

[10]  M. Gottesman,et al.  P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. , 2003, Cancer research.

[11]  W. Hait,et al.  Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. , 2003, Cancer research.

[12]  J. Melo,et al.  MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. , 2003, Blood.

[13]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[14]  N. Déglon,et al.  Lentiviral-mediated RNA interference. , 2002, Human gene therapy.

[15]  R. Medzhitov,et al.  Retroviral delivery of small interfering RNA into primary cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[17]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[18]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[19]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[20]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[21]  D. Stuart,et al.  A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1 , 2000, Cancer Gene Therapy.

[22]  A. Baryshnikov,et al.  Prognostic value of P-glycoprotein and leukocyte differentiation antigens in chronic myeloid leukemia. , 1998, Leukemia & lymphoma.

[23]  R. Plasterk,et al.  Molecular Reconstruction of Sleeping Beauty , a Tc1-like Transposon from Fish, and Its Transposition in Human Cells , 1997, Cell.

[24]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[25]  P. Holm,et al.  Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. , 1994, British Journal of Cancer.

[26]  T. Dorai,et al.  Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. , 1994, Cancer research.

[27]  Hatem Zayed,et al.  The Sleeping Beauty transposable element: evolution, regulation and genetic applications. , 2004, Current issues in molecular biology.

[28]  J. Griffin,et al.  Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.